Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive
The purpose of this study is to determine whether narrowband imaging (NBI) makes it easier for a surgeon to see cancer. NBI is a kind of light. Normally, white light is used during surgery. White light uses many wavelengths of light. NBI only uses two wavelengths which highlight the blood vessels. This makes it easier for the surgeon to see blood vessels. Tumors often have more blood vessels than normal tissue. As a result, NBI may make it easier for the surgeon to see small tumors. In this study the surgeon will look with both normal white light and NBI. This way a comparison can be made to determine which is superior. Improved identification of tumors allows doctors and patients to make informed decisions about whether treatment is needed after surgery. It also provides additional information to determine which treatments may be best.
Checked against the public recordLast updated Nov 7, 2018 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Diagnostic
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Interventions being studied
- Other: Narrow Band Imaging (NBI)
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Patients must meet one (or more) of the following criteria: * Preoperative diagnosis of ovarian, fallopian tube, or primary peritoneal carcinoma (all stage, grade and histology) * Preoperative diagnosis of grade III endometrial carcinoma (all stage, all histology) * Preoperative diagnosis of uterine serous carcinoma (all stage, all grade) * Preoperative diagnosis of clear cell endometrial carcinoma (all stage, all grade) * Preoperative diagnosis of endometrial carcinosarcoma (all stage, all grade) * Gastrointestinal carcinoma (all histology, stage and grade) * Pancreatic carcinoma (all histology, stage and grade) * Lung cancer (all histology, stage and grade) * Esophageal carcinoma (all histology, stage and grade) * Suspected or pathologically confirmed metastatic disease to the lung (all disease primaries) * Suspected or pathologically confirmed malignant pleural effusion (all disease primaries) Patients must meet all of the following criteria: * Planned thorascopic robotic or laparoscopic surgical approach * \>18 years old * Not pregnant * Able to give consent Participation in other research protocols does not exclude a patient from participation in this study. Exclusion Criteria: * None
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Memorial Sloan Kettering Cancer CenterNew York, New York
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 7, 2018. Always confirm current availability with the study team.